1. Home
  2. RNTX vs ANGH Comparison

RNTX vs ANGH Comparison

Compare RNTX & ANGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.26

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Logo Anghami Inc.

ANGH

Anghami Inc.

N/A

Current Price

$3.45

Market Cap

25.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
ANGH
Founded
2001
2012
Country
United States
United Arab Emirates
Employees
11
186
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.0M
25.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RNTX
ANGH
Price
$1.26
$3.45
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
96.1K
3.1K
Earning Date
05-14-2026
12-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.25
52 Week High
$2.22
$7.05

Technical Indicators

Market Signals
Indicator
RNTX
ANGH
Relative Strength Index (RSI) 51.38 59.60
Support Level $1.07 $2.83
Resistance Level $1.30 $3.46
Average True Range (ATR) 0.12 0.24
MACD -0.00 0.07
Stochastic Oscillator 42.86 79.64

Price Performance

Historical Comparison
RNTX
ANGH

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.

Share on Social Networks: